Dimesna

Drug Profile

Dimesna

Alternative Names: BNP 7787; Disodium 2,2'-dithio-bis ethane sulfonate; LP 300; Tavocept

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioNumerik Pharmaceuticals
  • Developer BioNumerik Pharmaceuticals; Lantern Pharma
  • Class Alkanesulfonates; Chemoprotectants; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Antioxidants; Glutaredoxin modulators; Thioredoxin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Lung cancer
  • Phase II Non-small cell lung cancer
  • No development reported Peripheral nervous system diseases

Most Recent Events

  • 02 May 2017 Phase-II clinical trials in Non-small cell lung cancer in USA (IV) (Lantern Pharma pipeline, May 2017)
  • 17 Jan 2017 Lantern Pharma enters into a strategic collaboration agreement with Cancer Genetics Incorporated
  • 22 Apr 2015 Phase III development is ongoing in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top